Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results

Tadahiko Fujino, Naoki Hasegawa, Reiko Satou, Hirokazu Komatsu, Kanemitsu Kawada

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirty six cases with multidrug-resistant tuberculosis were retrospectively studied to define the causes attributable to the emergence of multidrug-resistant M. tuberculosis. All these tuberculosis cases were microbiologically confirmed and resistant to at least isoniazid and rifampicin. Data analysis using matched-pair sampling methods (1:3) demonstrated that the followings are the significant risk factors for the emergence of multidrug-resistant tuberculosis; incompliance to treatment (Odds ratio 21.0: 95%Cl 4.10-107.63), alcohol abuse (Odds ratio 15.0 : 95%Cl 2.34-96.1) and the history of previous treatment (Odds ratio 5.0 : 95%Cl 2.04-12.21), while diabetes mellitus is not statistically significant. The incompliance to treatment which is primarily thought to be patient's responsibility results in non-optimal administration of antituberculous agents, leading to the multidrug-resistant tuberculosis. Other factors that may have contributed to the emergence of resistance included the unnecessary change of regimen before completion of chemotherapy. This is patient- unrelated situation where responsibility lies in the medical side. A clinical case presented here is an example. In this case RFP was replaced with ethambutol 3-months after the initiation of regimen including SM, INH and RFP because of abnormal elevation of GOT and GPT without any supporting evidence that RFP was causative. The readministration of RFP after 1-year cessation did not induce liver dysfunction, while the drug resistance was observed not only to RFP but also to INH. This case suggests unnecessary interruption of RFP could lead to the emergence of resistance to INH as well as RFP. One known mechanism of drug resistance is random mutation and the selection by drugs administered during the course of chemotherapy. The cases with advanced cavitary lesions would have a higher probability of the occurrence of mutation. The more the number of mutant bacilli, the higher the probability of emergence of multidrug resistance. Those cases in which longer period of time is needed for the negative conversion of M. tuberculosis should be treated with potent chemotherapy regimens under the intensive supervision. Since both INH and RFP are the most potent among currently available antituberculous agents. It is crucial to preserve the potency of these essential agents before novel antituberculous are developed.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalKekkaku
Volume73
Issue number7
Publication statusPublished - 1998 Jul
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Mycobacterium tuberculosis
Drug Resistance
Observation
Odds Ratio
Drug Therapy
Ethambutol
Mutation
Isoniazid
Multiple Drug Resistance
Rifampin
Mycobacterium
Bacillus
Alcoholism
Liver Diseases
Diabetes Mellitus
Tuberculosis
Therapeutics
History
Pharmaceutical Preparations

Keywords

  • Incompliance
  • INH · RFP
  • Multidrug-resistant tuberculosis
  • Pulmonary tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results. / Fujino, Tadahiko; Hasegawa, Naoki; Satou, Reiko; Komatsu, Hirokazu; Kawada, Kanemitsu.

In: Kekkaku, Vol. 73, No. 7, 07.1998, p. 471-476.

Research output: Contribution to journalArticle

@article{c36e169eef1e4934975829a9e9a5fee6,
title = "Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results",
abstract = "Thirty six cases with multidrug-resistant tuberculosis were retrospectively studied to define the causes attributable to the emergence of multidrug-resistant M. tuberculosis. All these tuberculosis cases were microbiologically confirmed and resistant to at least isoniazid and rifampicin. Data analysis using matched-pair sampling methods (1:3) demonstrated that the followings are the significant risk factors for the emergence of multidrug-resistant tuberculosis; incompliance to treatment (Odds ratio 21.0: 95{\%}Cl 4.10-107.63), alcohol abuse (Odds ratio 15.0 : 95{\%}Cl 2.34-96.1) and the history of previous treatment (Odds ratio 5.0 : 95{\%}Cl 2.04-12.21), while diabetes mellitus is not statistically significant. The incompliance to treatment which is primarily thought to be patient's responsibility results in non-optimal administration of antituberculous agents, leading to the multidrug-resistant tuberculosis. Other factors that may have contributed to the emergence of resistance included the unnecessary change of regimen before completion of chemotherapy. This is patient- unrelated situation where responsibility lies in the medical side. A clinical case presented here is an example. In this case RFP was replaced with ethambutol 3-months after the initiation of regimen including SM, INH and RFP because of abnormal elevation of GOT and GPT without any supporting evidence that RFP was causative. The readministration of RFP after 1-year cessation did not induce liver dysfunction, while the drug resistance was observed not only to RFP but also to INH. This case suggests unnecessary interruption of RFP could lead to the emergence of resistance to INH as well as RFP. One known mechanism of drug resistance is random mutation and the selection by drugs administered during the course of chemotherapy. The cases with advanced cavitary lesions would have a higher probability of the occurrence of mutation. The more the number of mutant bacilli, the higher the probability of emergence of multidrug resistance. Those cases in which longer period of time is needed for the negative conversion of M. tuberculosis should be treated with potent chemotherapy regimens under the intensive supervision. Since both INH and RFP are the most potent among currently available antituberculous agents. It is crucial to preserve the potency of these essential agents before novel antituberculous are developed.",
keywords = "Incompliance, INH · RFP, Multidrug-resistant tuberculosis, Pulmonary tuberculosis",
author = "Tadahiko Fujino and Naoki Hasegawa and Reiko Satou and Hirokazu Komatsu and Kanemitsu Kawada",
year = "1998",
month = "7",
language = "English",
volume = "73",
pages = "471--476",
journal = "Kekkaku",
issn = "0022-9776",
publisher = "Japanese Society for Tuberculosis",
number = "7",

}

TY - JOUR

T1 - Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results

AU - Fujino, Tadahiko

AU - Hasegawa, Naoki

AU - Satou, Reiko

AU - Komatsu, Hirokazu

AU - Kawada, Kanemitsu

PY - 1998/7

Y1 - 1998/7

N2 - Thirty six cases with multidrug-resistant tuberculosis were retrospectively studied to define the causes attributable to the emergence of multidrug-resistant M. tuberculosis. All these tuberculosis cases were microbiologically confirmed and resistant to at least isoniazid and rifampicin. Data analysis using matched-pair sampling methods (1:3) demonstrated that the followings are the significant risk factors for the emergence of multidrug-resistant tuberculosis; incompliance to treatment (Odds ratio 21.0: 95%Cl 4.10-107.63), alcohol abuse (Odds ratio 15.0 : 95%Cl 2.34-96.1) and the history of previous treatment (Odds ratio 5.0 : 95%Cl 2.04-12.21), while diabetes mellitus is not statistically significant. The incompliance to treatment which is primarily thought to be patient's responsibility results in non-optimal administration of antituberculous agents, leading to the multidrug-resistant tuberculosis. Other factors that may have contributed to the emergence of resistance included the unnecessary change of regimen before completion of chemotherapy. This is patient- unrelated situation where responsibility lies in the medical side. A clinical case presented here is an example. In this case RFP was replaced with ethambutol 3-months after the initiation of regimen including SM, INH and RFP because of abnormal elevation of GOT and GPT without any supporting evidence that RFP was causative. The readministration of RFP after 1-year cessation did not induce liver dysfunction, while the drug resistance was observed not only to RFP but also to INH. This case suggests unnecessary interruption of RFP could lead to the emergence of resistance to INH as well as RFP. One known mechanism of drug resistance is random mutation and the selection by drugs administered during the course of chemotherapy. The cases with advanced cavitary lesions would have a higher probability of the occurrence of mutation. The more the number of mutant bacilli, the higher the probability of emergence of multidrug resistance. Those cases in which longer period of time is needed for the negative conversion of M. tuberculosis should be treated with potent chemotherapy regimens under the intensive supervision. Since both INH and RFP are the most potent among currently available antituberculous agents. It is crucial to preserve the potency of these essential agents before novel antituberculous are developed.

AB - Thirty six cases with multidrug-resistant tuberculosis were retrospectively studied to define the causes attributable to the emergence of multidrug-resistant M. tuberculosis. All these tuberculosis cases were microbiologically confirmed and resistant to at least isoniazid and rifampicin. Data analysis using matched-pair sampling methods (1:3) demonstrated that the followings are the significant risk factors for the emergence of multidrug-resistant tuberculosis; incompliance to treatment (Odds ratio 21.0: 95%Cl 4.10-107.63), alcohol abuse (Odds ratio 15.0 : 95%Cl 2.34-96.1) and the history of previous treatment (Odds ratio 5.0 : 95%Cl 2.04-12.21), while diabetes mellitus is not statistically significant. The incompliance to treatment which is primarily thought to be patient's responsibility results in non-optimal administration of antituberculous agents, leading to the multidrug-resistant tuberculosis. Other factors that may have contributed to the emergence of resistance included the unnecessary change of regimen before completion of chemotherapy. This is patient- unrelated situation where responsibility lies in the medical side. A clinical case presented here is an example. In this case RFP was replaced with ethambutol 3-months after the initiation of regimen including SM, INH and RFP because of abnormal elevation of GOT and GPT without any supporting evidence that RFP was causative. The readministration of RFP after 1-year cessation did not induce liver dysfunction, while the drug resistance was observed not only to RFP but also to INH. This case suggests unnecessary interruption of RFP could lead to the emergence of resistance to INH as well as RFP. One known mechanism of drug resistance is random mutation and the selection by drugs administered during the course of chemotherapy. The cases with advanced cavitary lesions would have a higher probability of the occurrence of mutation. The more the number of mutant bacilli, the higher the probability of emergence of multidrug resistance. Those cases in which longer period of time is needed for the negative conversion of M. tuberculosis should be treated with potent chemotherapy regimens under the intensive supervision. Since both INH and RFP are the most potent among currently available antituberculous agents. It is crucial to preserve the potency of these essential agents before novel antituberculous are developed.

KW - Incompliance

KW - INH · RFP

KW - Multidrug-resistant tuberculosis

KW - Pulmonary tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0031814540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031814540&partnerID=8YFLogxK

M3 - Article

C2 - 9739579

AN - SCOPUS:0031814540

VL - 73

SP - 471

EP - 476

JO - Kekkaku

JF - Kekkaku

SN - 0022-9776

IS - 7

ER -